Risk factor
Meaningful price volatility
Profitability factor
Greatly undervalued vs peers
About
Blau Farmacêutica S.A. operates as a pharmaceutical enterprise, supplying private label medications across Brazil, Argentina, Colombia, the United States, Ecuador, Peru, and Uruguay. Its extensive product portfolio encompasses a broad spectrum of therapeutic areas, including immunology, hematology, oncology, nephrology, specialized treatments, and antibiotics. The company's offerings also extend to biological drugs, oral and injectable therapies for cancer, specialized treatments for infectious diseases, and a range of prescription and over-the-counter products like dermo-medicines and contraceptives, catering to both retail and non-retail markets. Additionally, Blau provides pharmaceuticals derived from blood, biological and biotechnological agents, and antiretroviral drugs. Its client base includes hospitals, private medical clinics, chemotherapy and hemodialysis centers, and public health institutions. Established in 1987, the firm's corporate headquarters are situated in Cotia, Brazil.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA, undervalue
Target Price
The average target price of BLAU3.SA is 13.5 and suggests 53.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to